ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“Interested in the latest developments in Breast Cancer?
Check out some of the most recent articles from ESMOBreast25:
- Adding adjuvant pertuzumab demonstrates prolonged survival benefit after 10+ years in HER2+ breast cancer.
- Who benefits from immunotherapy for breast cancer?
- Tailored use of chemotherapy may benefit some early-stage ER+/HER2– breast cancers.
- Promising early results for emiltatug ledadotin in heavily pretreated triple-negative breast cancer TNBC.
- Shaping the future for young women facing breast cancer.
Stay up-to-date with the cutting-edge developments in oncology.
Follow the ESMO Daily Reporter, your trusted source for news and expert opinions tailored to the Oncology Community.”
More posts featuring ESMO.